Synlogic 

Synlogic is a biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. 

The Company’s focus is on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934),  a potential treatment for phenylketonuria (PKU). Additional programs are targeting homocystinuria (HCU), enteric hyperoxaluria, gout and cystinuria, in addition to research in inflammatory bowel disease (IBD).  

This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics to create GI-restricted, oral medicines.  Founded in 2014 by MIT professors Jim Collins and Tim Lu, Synlogic combines synthetic biology, a multi-disciplinary field that applies principles of programming and engineering to biological parts and organisms. 

For more information, please visit www.synlogictx.com. Follow us on Twitter, LinkedIn, Facebook or Instagram.